yourstate.us
21 CFR 868.2376

§ 868.2376 Device for sleep apnea testing based on mandibular movement.

United States · 21 CFR — Food and Drugs · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 CFR 868.2376, § 868.2376 Device for sleep apnea testing based on mandibular movement, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/89753
Permanent ID
ys:prov:89753@1
SHA-256
6bffc99ea1ceb92ecf1e1b1a99d23ad998f8435d0ac5b8949a9c92fd0a5d2645

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Identification. A device for sleep apnea testing based on mandibular movement is a prescription device intended to aid in evaluation of sleep apnea during sleep in patients suspected of having sleep breathing disorders by analyzing sensor readings of mandibular movement. The device is not intended as a substitute for full polysomnography nor intended to be used as an apnea monitor. (b) Classification. Class II (special controls). The special controls for this device are: (1) Clinical data must be provided. This assessment must fulfill the following: (i) The clinical data must be representative of the intended use population for the device. Any selection criteria or sample limitations must be fully described and justified. (ii) The assessment must demonstrate output consistency using the expected range of data sources and data quality encountered in the intended use population and environment. (iii) The assessment must compare device performance with a clinical comparator device (e.g., polysomnography). (2) The patient-contacting components of the device must be demonstrated to be biocompatible. (3) The performance data must be provided to demonstrate the electromagnetic compatibility and electrical, mechanical, and thermal safety of the device. (4) A software description and the results of verification and validation testing based on a comprehensive hazard analysis and risk assessment must include: (i) A full characterization of the software technical parameters, including algorithms; (ii) A description of the expected impact of all applicable sensor acquisition hardware characteristics and associated hardware specifications; and (iii) A description of all mitigations for failure of any subsystem components (including signal detection, signal analysis, data display, and storage) on output accuracy. (5) Labeling must include: (i) A description of what the device measures and outputs to the user; (ii) Warnings identifying sensor acquisition factors or subject conditions or characteristics (e.g., conditions affecting the anatomy of the recording site, or subject conditions that may affect mandibular movement) that may impact measurement results; (iii) Guidance for interpretation of the measurements, including a statement that the device is not intended as a substitute for full polysomnography nor intended to be used as an apnea monitor; and (iv) The expected performance of the device for all intended use populations and environments.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.